ATE223210T1 - Die verwendung eines gp iib/iiia antagonisten für die herstellung eines medikamentes geeignet zur transdermalen applikation mittels iontophorese - Google Patents

Die verwendung eines gp iib/iiia antagonisten für die herstellung eines medikamentes geeignet zur transdermalen applikation mittels iontophorese

Info

Publication number
ATE223210T1
ATE223210T1 AT99107216T AT99107216T ATE223210T1 AT E223210 T1 ATE223210 T1 AT E223210T1 AT 99107216 T AT99107216 T AT 99107216T AT 99107216 T AT99107216 T AT 99107216T AT E223210 T1 ATE223210 T1 AT E223210T1
Authority
AT
Austria
Prior art keywords
iontophoresis
iib
iiia antagonist
production
transdermal application
Prior art date
Application number
AT99107216T
Other languages
English (en)
Inventor
Katsumi Iga
Yukihiro Matsumoto
Shigeo Yanai
Original Assignee
Hisamitsu Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co filed Critical Hisamitsu Pharmaceutical Co
Application granted granted Critical
Publication of ATE223210T1 publication Critical patent/ATE223210T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99107216T 1998-04-14 1999-04-14 Die verwendung eines gp iib/iiia antagonisten für die herstellung eines medikamentes geeignet zur transdermalen applikation mittels iontophorese ATE223210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10252198 1998-04-14

Publications (1)

Publication Number Publication Date
ATE223210T1 true ATE223210T1 (de) 2002-09-15

Family

ID=14329656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99107216T ATE223210T1 (de) 1998-04-14 1999-04-14 Die verwendung eines gp iib/iiia antagonisten für die herstellung eines medikamentes geeignet zur transdermalen applikation mittels iontophorese

Country Status (5)

Country Link
US (1) US6322550B2 (de)
EP (1) EP0950407B1 (de)
AT (1) ATE223210T1 (de)
CA (1) CA2269050A1 (de)
DE (1) DE69902713T2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414517B2 (ja) * 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US6623664B2 (en) * 1999-12-24 2003-09-23 3M Innovative Properties Company Conductive adhesive and biomedical electrode
US7162137B2 (en) * 2001-06-20 2007-01-09 Ers Company Optical fiber with nano-particle cladding
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
ES2428027T3 (es) * 2002-05-20 2013-11-05 Otsuka Pharmaceutical Co., Ltd. Composición que comprende adenosín-monofosfato para el tratamiento del melasma
WO2004047916A1 (ja) * 2002-11-27 2004-06-10 Tokuyama Corporation イオントフォレーシス装置
DE10356346A1 (de) * 2003-11-28 2005-06-23 TransMIT Gesellschaft für Technologietransfer mbH Erfindung betreffend Prophylaxe und Therapie von Erkrankungen, die durch Thrombusbildung verusacht oder mit versacht werden
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
UY28935A1 (es) * 2004-06-03 2005-07-29 Alza Corp Sistema y metodo para la administracion transdermica de un anticoagulante
DE102005024040A1 (de) * 2005-05-25 2006-12-14 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Kosmetisches oder therapeutisches Kombinationspräparat mit Theanin
WO2010032140A2 (en) * 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
EP3253401A4 (de) 2015-02-03 2018-11-21 Chiasma Inc. Verfahren zur behandlung von krankheiten
SE545752C2 (en) * 2019-12-20 2023-12-27 Oboe Ipr Ab Selective drug delivery in an ion pump through proton entrapment
JP2023508907A (ja) 2019-12-20 2023-03-06 テナヤ セラピューティクス， インコーポレイテッド フルオロアルキル－オキサジアゾールおよびその使用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585002B2 (ja) 1987-07-02 1997-02-26 日東電工株式会社 経皮薬物投与用の電圧印加装置
JPS6411565A (en) 1987-07-03 1989-01-17 Nitto Denko Corp Drug admistrating method by iontophoresis
US5700481A (en) 1995-03-17 1997-12-23 Takeda Chemical Industries, Ltd. Transdermal drug delivery process
WO1996033982A1 (en) 1995-04-26 1996-10-31 Takeda Chemical Industries, Ltd. Piperazinones useful as inhibitors of platelet aggregation
US5983130A (en) * 1995-06-07 1999-11-09 Alza Corporation Electrotransport agent delivery method and apparatus
EP0747092B1 (de) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix für Iontophorese
ATE248004T1 (de) 1995-06-14 2003-09-15 Hisamitsu Pharmaceutical Co Schnittstelle für iontophorese
WO1997048443A1 (en) 1996-06-19 1997-12-24 Becton Dickinson And Company Iontophoretic delivery of cell adhesion inhibitors
WO1997048395A1 (en) 1996-06-19 1997-12-24 Du Pont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
GB9613096D0 (en) 1996-06-21 1996-08-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EP0950407A1 (de) 1999-10-20
DE69902713D1 (de) 2002-10-10
US6322550B2 (en) 2001-11-27
US20010018568A1 (en) 2001-08-30
DE69902713T2 (de) 2003-05-28
EP0950407B1 (de) 2002-09-04
CA2269050A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
ATE223210T1 (de) Die verwendung eines gp iib/iiia antagonisten für die herstellung eines medikamentes geeignet zur transdermalen applikation mittels iontophorese
CY1109641T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια λεμφωματος
PL357211A1 (en) Nanocapsules and method of production thereof
EP1193027A3 (de) Drehmaschine
SI0769967T1 (sl) Konjugati vsebujoäśi protitumorna sredstva in njihova uporaba
EP1181903A3 (de) Ein Stent für Angioplastik und damit verbundenes Produktionsverfahren
AU2067597A (en) Polymer-metal foil structure for neural stimulating electrodes
PT923570E (pt) Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
GB9415167D0 (en) Improvements relating to cancer therapy
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
DE69400337D1 (de) Mittel gegen Hautalterung, das gleichzeitig auf die Hautoberschichten und Tiefschichten wirkt
ES2150664T3 (es) Nuevos derivados peptidos.
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
ATE211135T1 (de) Aminocyclohexylester und ihre anwendung
DK0870089T3 (da) Overfladebehandlet sikkerhedspapir og metoder og anordninger til at fremstille overfladebehandlet sikkerhedspapir
GB2381539B (en) Paper incorporating a wide elongate impermeable element, and a method of makingof the same
AU6857887A (en) Therapeutic agent
ATE248216T1 (de) Ersatztherapie für zahnkaries
EP1634605A3 (de) Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
SE0102390L (sv) Arrangemang och förfarande för att tillhandahålla i främst titan utförda implantatfixturer
AU3603597A (en) Drug delivery devices and process of manufacture
MXPA04003428A (es) Tela que comprende elementos no tejidos para usarse en la fabricacion de productos de tisu que tienen regiones de textura de fondo visualmente discernibles bordeadas por elementos decorativos curvilineales y metodo para la fabricacion de los producto
AU8132587A (en) Penetration enhancers for transdermal delivery of systemic agents
JPS63152919U (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties